Promotie onderzoek

Nieuwe oncologische geneesmiddelen worden over het algemeen geregistreerd op basis van onderzoek met surrogaat eindpunten, een kleine populatie en/of beperkte inclusiecriteria. Dit onderzoek richt zich op (nieuwe) methodes om effectiviteit en veiligheid van deze geneesmiddelen in de praktijk te evalueren.

The (positive) effects of antihypertensive drugs in the cardiovascular risk management are undoubted. However, like all drugs, antihypertensive drugs also have negative side-effects. Especially the elderly, are more susceptible for these adverse effects. It's not clear whether the benefits outweight the risks. So is it possible to deprescribe antihypertensive drugs and minimise risks for adverse events, while maintining blood-pressure levels in accordance with guidelines?  

1. Stress-relieving: 3D printing personalized cortisol for patients with adrenal insufficiency
2. A novel delayed release hydrocortison formulation for patients with adrenal insufficiency
3. Feasibility study of 10 mg 3D printed systained release hydrocortisone 
4. Feasibility study of 3D printed delayed release hydrocortisone 
5. RCT of novel 3D printed hydrocortisone vs standard of care in adrenal insufficiency 

Drug repositioning is the application of existing drugs to new indications. We want to find out if it is possible to find new potentially effective drugs against individual tumors based on their unique gene expression patterns.